- Overview:
- This is a study to observe the effects of CagriSema on heart disease in people living with obesity, and diseases of the heart and blood vessels.
- Staus:
- Enrolling
- Clinical Description:
- This study will evaluate the effects of CagriSema on cardiovascular events in people living with obesity and cardiovascular disease. The participants with either get CagriSema or Placebo.
- Target Age/Sex:
- Male & Female, age 55 years or above BMI of >30 with established cardiac disease
- Benefits:
- Participants will receive at no cost: study product, study materials and study-specific procedures.
- Study Length:
- Approximately 3 Years
- Link:
- ClinicalTrials.gov
